Literature DB >> 7473146

Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor?

P K Rangachari1, P A Betti, E T Prior, L J Roberts.   

Abstract

Earlier studies showed that PGD2 produced both increases and decreases in short-circuit current across the canine proximal colon. PGD2 metabolites had opposing effects: 11 beta-PGF2 alpha elicited only increases in Isc, and 13,14-dihydro-15-keto-PGD2 elicited only decreases. The stimulant effects involved FP receptors, but the receptors involved in mediating the inhibitory effects remained undefined. Here we show that the tissue, although it is capable of producing both PGD2 and PGE2, did not produce 11 beta-PGF2 alpha in measurable amounts. The selective DP receptor agonist BW 245C did not mimic the inhibitory effects of PGD2, producing only dose-dependent increases in short-circuit current. Further, these responses were not significantly inhibited by BW A868C. Cross-desensitization experiments suggested that the stimulant effects of BW 245C involved the EP receptor. However, on a standard preparation (rabbit platelets), both PGD2 and BW 245C inhibited ADP-induced aggregation and were antagonized by BW A868C. 11 beta-PGF2 alpha had no effects. The decreases in short-circuit current across the canine colonic epithelium elicited by PGD2 and 13,14-dihydro-15-keto PGD2 are not mimicked by other prostanoids, nor by the selective agonist BW 245C, and thus appear to involve receptors other than the classical DP receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7473146

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.

Authors:  Nicole Sawyer; Elizabeth Cauchon; Anne Chateauneuf; Rani P G Cruz; Donald W Nicholson; Kathleen M Metters; Gary P O'Neill; Francois G Gervais
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice.

Authors:  Abdullah Shafique Ahmad; Muzamil Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Age (Dordr)       Date:  2010-03-05

Review 3.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

4.  Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists.

Authors:  J Y Crider; B W Griffin; N A Sharif
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

5.  Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds.

Authors:  D F Woodward; A H Krauss; J Chen; D W Gil; K M Kedzie; C E Protzman; L Shi; R Chen; H A Krauss; A Bogardus; H T Dinh; L A Wheeler; S W Andrews; R M Burk; T Gac; M B Roof; M E Garst; L J Kaplan; G Sachs; K L Pierce; J W Regan; R A Ross; M F Chan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

6.  Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand.

Authors:  N A Sharif; G W Williams; T L Davis
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

Review 7.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

8.  Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2.

Authors:  H Hirai; K Tanaka; O Yoshie; K Ogawa; K Kenmotsu; Y Takamori; M Ichimasa; K Sugamura; M Nakamura; S Takano; K Nagata
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.